ES2274795T3 - Pirazinonas, composiciones que contienen tales compuestos. - Google Patents

Pirazinonas, composiciones que contienen tales compuestos. Download PDF

Info

Publication number
ES2274795T3
ES2274795T3 ES00947711T ES00947711T ES2274795T3 ES 2274795 T3 ES2274795 T3 ES 2274795T3 ES 00947711 T ES00947711 T ES 00947711T ES 00947711 T ES00947711 T ES 00947711T ES 2274795 T3 ES2274795 T3 ES 2274795T3
Authority
ES
Spain
Prior art keywords
alkyl
aryl
het
halo
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00947711T
Other languages
English (en)
Spanish (es)
Inventor
Yongxin Han
Andre Giroux
Robert Zamboni
Daniel J. Mckay
Christopher I. Bayly
Erich L. Grimm
John Colucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Application granted granted Critical
Publication of ES2274795T3 publication Critical patent/ES2274795T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
ES00947711T 1999-07-19 2000-07-17 Pirazinonas, composiciones que contienen tales compuestos. Expired - Lifetime ES2274795T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14446699P 1999-07-19 1999-07-19
US144466P 1999-07-19
US17061499P 1999-12-14 1999-12-14
US170614P 1999-12-14

Publications (1)

Publication Number Publication Date
ES2274795T3 true ES2274795T3 (es) 2007-06-01

Family

ID=26842025

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00947711T Expired - Lifetime ES2274795T3 (es) 1999-07-19 2000-07-17 Pirazinonas, composiciones que contienen tales compuestos.

Country Status (9)

Country Link
US (2) US6444811B1 (enExample)
EP (1) EP1202976B1 (enExample)
JP (1) JP4749640B2 (enExample)
AT (1) ATE344249T1 (enExample)
AU (1) AU773317B2 (enExample)
CA (1) CA2378834C (enExample)
DE (1) DE60031686T2 (enExample)
ES (1) ES2274795T3 (enExample)
WO (1) WO2001005772A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1202976B1 (en) * 1999-07-19 2006-11-02 Merck Frosst Canada Ltd. Pyrazinones, compositions containing such compounds
US20020155172A1 (en) * 2000-04-07 2002-10-24 Junying Yuan Methods and compounds for decreasing cell toxicity or death
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
AU2002246065A1 (en) * 2001-01-26 2002-08-06 Evotec Oai Ag Methods and means for detecting enzymatic cleavage and linkage reactions
FR2827288B1 (fr) * 2001-07-12 2003-10-31 Servier Lab Nouveaux derives d'octahydro-2h-pyrido[1,2-a]pyrazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2003211052A1 (en) 2002-02-11 2003-09-04 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
US7960398B2 (en) 2002-04-19 2011-06-14 Vertex Pharmaceuticals Incorporated Regulation of TNF-alpha
GB2417360B (en) 2003-05-20 2007-03-28 Kagutech Ltd Digital backplane
HUE024556T2 (hu) 2004-03-12 2016-02-29 Vertex Pharma Eljárások és intermedierek aszparagin acetál kapszáz inhibitorok elõállítására
CA2567080A1 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
US7879891B2 (en) 2005-07-28 2011-02-01 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
KR20080042286A (ko) * 2006-11-09 2008-05-15 주식회사 엘지생명과학 피리다지논 구조를 포함하는 캐스파제 저해제
WO2009019115A1 (en) 2007-08-03 2009-02-12 Sanofi-Aventis Caspase imaging probes
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
US9116157B2 (en) 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker
CN109180690A (zh) * 2018-10-15 2019-01-11 烟台显华化工科技有限公司 一类用作蓝色荧光材料的氮杂芳香化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
WO1999011267A1 (en) 1997-09-05 1999-03-11 Merck & Co., Inc. Pyrazinone thrombin inhibitors
NZ331993A (en) * 1996-04-23 2000-04-28 Merck & Co Inc Pyrazinone thrombin inhibitors
EP0934305A4 (en) 1996-08-29 2001-04-11 Merck & Co Inc INTEGRINANTAGONISTS
US5981546A (en) * 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
JP4199309B2 (ja) * 1996-09-06 2008-12-17 日本化薬株式会社 新規アセトアミド誘導体およびプロテアーゼ阻害
AU728006B2 (en) 1997-03-24 2001-01-04 Merck & Co., Inc. Thrombin inhibitors
US5866573A (en) 1997-04-21 1999-02-02 Merck & Co., Inc. Pyrazinone thrombin inhibitors
EP1202976B1 (en) * 1999-07-19 2006-11-02 Merck Frosst Canada Ltd. Pyrazinones, compositions containing such compounds

Also Published As

Publication number Publication date
CA2378834A1 (en) 2001-01-25
DE60031686T2 (de) 2007-08-30
AU773317B2 (en) 2004-05-20
EP1202976A1 (en) 2002-05-08
AU6143200A (en) 2001-02-05
EP1202976B1 (en) 2006-11-02
JP2003505378A (ja) 2003-02-12
ATE344249T1 (de) 2006-11-15
US6444811B1 (en) 2002-09-03
US20030236402A1 (en) 2003-12-25
CA2378834C (en) 2009-07-07
DE60031686D1 (de) 2006-12-14
WO2001005772A1 (en) 2001-01-25
JP4749640B2 (ja) 2011-08-17
US6699856B2 (en) 2004-03-02

Similar Documents

Publication Publication Date Title
ES2274795T3 (es) Pirazinonas, composiciones que contienen tales compuestos.
ES2394177T3 (es) 1,4-diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos
ES2262824T3 (es) Compuestos de n-formil hidroxilamina como inhibidores de pdf.
JP2002528495A (ja) ニトロソ化およびニトロシル化された非ステロイド抗炎症性化合物、組成物および使用方法
WO2003024955A2 (en) Small molecule inhibitors of caspases
JPH02124862A (ja) シクロアルキル置換されたグルタルアミド抗高血圧剤
US6225288B1 (en) Gamma-ketoacid dipeptides as inhibitors of caspase-3
AU758739B2 (en) Heterocyclic compounds, intermediates thereof and elastase inhibitors
SG182535A1 (en) Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen
US8119673B2 (en) Compounds 148
ES2380632T3 (es) Derivados de ácido3-(2-(3-ACILAMINO-2-OXO-2H-PIRIDIN)-ACETILAMINO)-4-OXO-PENTANOICO y su uso como inhibidores de caspasas
AU764860B2 (en) Gamma-ketoacid tetrapeptides as inhibitors of caspase-3
ES2308002T3 (es) Derivados de pirrolidin-2-ona como inhibidores de trombina y factor xa.
US6525025B2 (en) Gamma-ketoacid dipeptides as inhibitors of caspase-3
US20030045478A1 (en) Gamma-ketoacid dipeptide derivatives as inhibitors of caspase-3
CA2386411A1 (en) Nicotinyl aspartyl ketones as inhibitors of caspase-3
HK1064370B (en) N-formyl hydroxylamine compounds as inhibitors of pdf
JP2005529147A (ja) ヘキサヒドロピリダジン−３−カルボン酸誘導体、該誘導体を含有する医薬組成物およびその製法